↓ Skip to main content

Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid

Overview of attention for article published in BONE, April 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

twitter
3 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid
Published in
BONE, April 2015
DOI 10.1016/j.bone.2014.12.011
Pubmed ID
Authors

Frédéric Lézot, Julie Chesneau, Benjamin Navet, Bérengère Gobin, Jérome Amiaud, YongWon Choi, Hideo Yagita, Beatriz Castaneda, Ariane Berdal, Christopher G. Mueller, Françoise Rédini, Dominique Heymann

Abstract

High doses of bone resorption inhibitors are currently under evaluation in pediatric oncology. Previous works have evidenced transient arrest in long bone and skull bone growth and tooth eruption blockage when mice were treated with zoledronic acid (ZOL). The question of potential similar effects with a RANKL-blocking antibody (IK22.5) was raised. Sensitivity disparities in these inhibitors between mouse strains and synergic effects of zoledronic acid and a RANKL-blocking antibody were subsidiary questions. In order to answer these questions, newborn C57BL/6J and CD1 mice were injected every two or three days (4 injections in total so 7 or 10days of treatment length) with high doses of a RANKL-blocking antibody. The consequences on the tibia, craniofacial bones and teeth were analyzed by μCT and histology at the end of the treatment and one, two and three months later. The results obtained showed that RANKL-blocking antibody injections induced a transient arrest of tibia and skull bone growth and an irreversible blockage of tooth eruption in C57BL/6J mice. In CD1 mice, tooth eruption defects were also present but only at much higher doses. Similar mouse strain differences were obtained with zoledronic acid. Finally, a synergic effect of the two inhibitors was evidenced. In conclusion as previously observed for bisphosphonates (ZOL), a RANKL-blocking antibody induced a transient arrest in long bone and skull bone growth and a blockage of tooth eruption with however disparities between mouse strains with regard to this last effect. A synergic effect of both bone resorption inhibitors was also demonstrated.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 22%
Student > Master 6 22%
Student > Doctoral Student 3 11%
Student > Ph. D. Student 3 11%
Professor 2 7%
Other 2 7%
Unknown 5 19%
Readers by discipline Count As %
Medicine and Dentistry 10 37%
Agricultural and Biological Sciences 5 19%
Biochemistry, Genetics and Molecular Biology 3 11%
Social Sciences 1 4%
Immunology and Microbiology 1 4%
Other 4 15%
Unknown 3 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 February 2015.
All research outputs
#7,383,892
of 12,299,540 outputs
Outputs from BONE
#1,634
of 2,843 outputs
Outputs of similar age
#127,652
of 270,811 outputs
Outputs of similar age from BONE
#22
of 71 outputs
Altmetric has tracked 12,299,540 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,843 research outputs from this source. They receive a mean Attention Score of 3.7. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,811 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.